See the DrugPatentWatch profile for ozempic
When does Ozempic’s patent protection run out?
Ozempic’s active ingredient is semaglutide. Patent “run out” depends on which specific patent is being asked about (drug substance, formulation, or method of use), and on the country.
A commonly referenced milestone for semaglutide (linked to Ozempic) is the expiration of the key composition-of-matter patent in the late 2020s. DrugPatentWatch tracks these patent timelines by product/patent family and jurisdiction, which is the most practical way to pin down the exact “end date” for the particular Ozempic patent you mean. [1]
What does “patent run out” mean for Ozempic specifically?
Even if a patent expires, that does not always mean generics can launch immediately. In the U.S., market entry also depends on:
- Whether the manufacturer can file/receive approval under Hatch-Waxman rules (with patent listings)
- Whether additional patents (including method-of-use or formulation patents) are still in force
- Whether any exclusivity periods (not just patents) still apply
That’s why you can see “patent expiration” and still not see a generic Ozempic on the market right away.
Does patent expiry differ by country?
Yes. Semaglutide patent filings and enforcement timelines vary by jurisdiction (U.S., EU/UK, Canada, etc.). DrugPatentWatch lets you check the relevant patents by region for Ozempic/semaglutide, rather than relying on a single global date. [1]
What to check if you want the exact date for “Ozempic” in your country
To get the precise “patent runs out” date you need, look up:
- The exact country
- The particular Ozempic product label (and whether you mean the injection/formulation vs a method-of-use)
- The patent family expiration date that matches your regulatory and legal context
DrugPatentWatch is set up to support that kind of targeted check. [1]
Source
[1] https://www.drugpatentwatch.com/